BioCentury
ARTICLE | Clinical News

Signature reports Detector C data

June 4, 2010 11:21 PM UTC

Signature Diagnostics AG (Potsdam, Germany) said Detector C had 90% sensitivity and 88% specificity for all four stages of colorectal cancer in a prospective validation study of blood samples from patients with confirmed colorectal cancer and healthy controls undergoing a colonoscopy for screening purposes. Specifically, sensitivity for stage I, II, III and IV colorectal cancer was 89%, 90%, 90% and 93%, respectively. Data will be presented at the American Society of Clinical Oncology meeting, which began on Friday in Chicago. ...